Researchers at McMaster University identified a large set of genes in Streptomyces bacteria that together generate four antibiotics. These compounds act jointly to deprive competing microbes of biotin, an essential nutrient. The study, published in Nature, outlines an extended DNA region that codes for four separate families of natural products. One substance is new to science, while another had not previously been seen as an antibiotic. The molecules interfere with biotin production, uptake, and function, presenting a coordinated strategy against rival cells. Biotin, or vitamin B7, supports bacterial growth and division. Disrupting its pathways offers a fresh model for combined antibiotic action and a possible route to treat resistant infections. Professor Eric Brown described the process as a deliberate siege on multiple fronts. The gene cluster sits beside two streptavidin genes that enable the bacteria to produce biotin-binding proteins. This placement lets the producer organisms secure available biotin while the antibiotics block access by competitors. The arrangement occurs across many Streptomyces species, suggesting the system arose long ago and has been retained. Analysis indicated the cluster appears more widely than genes for streptomycin, an earlier antibiotic from the same bacteria. Tests in animal models of infection showed two of the compounds worked well against multidrug-resistant E. coli. The approach could make resistance harder to develop, since several separate changes would be required for protection. Standard lab media contain high nutrient levels that may hide the activity of such compounds during routine screening.
